NLS Agreement

NeuroVive Pharmaceutical announced that a collaboration agreement has been signed with Karolinska Institutet regarding development of the company’s compound NV556 for the treatment of mitochondrial myopathy. Under the collaboration agreement, the team led by Prof. Hakan Westerblad at Karolinska Institutet will study NeuroVive’s cyclophilin inhibitor compound NV556 and its effects in experimental models of mitochondrial […]

Elekta, Stockholm’s County Council and New Karolinska Solna have signed a 13-year collaboration agreement which focuses on innovation, joint research, and education and training within advanced radiation therapy. The aim of the agreement is to bring significant improvements in access, quality of care and clinical outcomes for patients suffering from cancer. As part of the […]

BioInvent International has entered into a cancer immunotherapy research collaboration and license agreement with Pfizer to develop antibodies targeting tumour-associated myeloid cells. Under the terms of the deal, Pfizer will pay BioInvent approximately $10 million in early payments, including an upfront payment, early research funding, and a $6 million equity investment in new shares of […]

Uppsala Innovation Centre (UIC) has signed an agreement with the newly established Turku Life Science accelerator, the first Finnish accelerator with a life science focus. The aim with the collaboration is to increase the possibilities for synergies, business and knowledge exchange betwwen companies in Finland and Sweden. UIC and Turku Life Science accelerator has signed […]

Gyros Protein Technologies has appointed Abacus ALS as exclusive distributor of its immunoassay products in Australia and New Zealand. Abacus ALS, an ISO 9001: 2008 accredited organization, is one of Australia’s and New Zealand’s largest privately owned companies serving customers in the diagnostic pathology, research and healthcare education industries. Abacus ALS will be responsible for […]

MedImmune and Abpro have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). The agreement is structured as a spin out, benefiting from both companies’ scientific expertise and Abpro’s day-to-day leadership as it oversees the new company, AbMed. Several potential therapeutic […]